
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 5 February 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 3MB, 220 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
Export 40 results:
Author [ Title
Filters: Author is Prieto-Alhambra, D. [Clear All Filters]
“Validation of hip osteoarthritis diagnosis recording in the UK Clinical Practice Research Datalink”, Pharmacoepidemiol Drug Saf, 2018.
, “Trends and determinants of length of stay and hospital reimbursement following knee and hip replacement: evidence from linked primary care and NHS hospital records from 1997 to 2014”, BMJ Open, vol. 8, p. e019146, 2018.
, “Treatment of first-time traumatic anterior shoulder dislocation: the UK TASH-D cohort study”, Health Technol Assess, vol. 23, pp. 1-104, 2019.
, , ,
“Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK”, Osteoporos Int, vol. 29, pp. 467-478, 2018.
, “Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study”, Lancet Rheumatol, vol. 2, pp. e698-e711, 2020.
, “Risk of hand osteoarthritis in new users of hormone replacement therapy: A nested case-control analysis”, Maturitas, vol. 132, pp. 17-23, 2020.
, “Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients”, Alzheimers Dement (N Y), vol. 3, pp. 612-621, 2017.
, “Programme Grants for Applied Research”, in Lower limb arthroplasty: can we produce a tool to predict outcome and failure, and is it cost-effective? An epidemiological study, Southampton (UK): NIHR Journals Library Copyright (c) Queen's Printer and Controller of HMSO 2017. This work was produced by Arden et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the pu, 2017.
, “Population trends in the incidence and initial management of osteoarthritis: age-period-cohort analysis of the Clinical Practice Research Datalink, 1992-2013”, Rheumatology (Oxford), vol. 56, pp. 1902-1917, 2017.
, “Oral bisphosphonate use and all-cause mortality in patients with moderate-severe (grade 3B-5D) chronic kidney disease: a population-based cohort study”, J Bone Miner Res, 2020.
, “Oral bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study”, Ann N Y Acad Sci, vol. 1415, pp. 34-46, 2018.
, “Models of care for the delivery of secondary fracture prevention after hip fracture: a health service cost, clinical outcomes and cost-effectiveness study within a region of England”, Health Services and Delivery Research, vol. No. 4.28, 2016.
, “The impact of different strategies to handle missing data on both precision and bias in a drug safety study: a multidatabase multinational population-based cohort study”, Clin Epidemiol, vol. 10, pp. 643-654, 2018.
, , “Hormone replacement therapy and mid-term implant survival following knee or hip arthroplasty for osteoarthritis: a population-based cohort study”, Ann Rheum Dis, vol. 74, pp. 557-63, 2015.
, , “Geographic variation in secondary fracture prevention after a hip fracture during 1999-2013: a UK study”, Osteoporos Int, vol. 28, pp. 169-178, 2017.
, “Future projections of total hip and knee arthroplasty in the UK: results from the UK Clinical Practice Research Datalink”, Osteoarthritis Cartilage, vol. 23, pp. 594-600, 2015.
, “Fracture risk before and after total hip replacement in patients with osteoarthritis: potential benefits of bisphosphonate use”, Arthritis Rheum, vol. 63, pp. 992-1001, 2011.
, “Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries”, Clin Epidemiol, vol. 12, pp. 423-433, 2020.
, “Encounters for foot and ankle pain in UK primary care: a population-based cohort study of CPRD data”, Br J Gen Pract, vol. 69, pp. e422-e429, 2019.
, “The effect of patient age at intervention on risk of implant revision after total replacement of the hip or knee: a population-based cohort study”, Lancet, vol. 389, pp. 1424-1430, 2017.
, “The effect of body mass index on the risk of post-operative complications during the 6 months following total hip replacement or total knee replacement surgery”, Osteoarthritis Cartilage, vol. 22, pp. 918-27, 2014.
, , , ,
“Costs of joint replacement in osteoarthritis: a study using the National Joint Registry and Clinical Practice Research Datalink datasets”, Arthritis Care Res (Hoboken), 2020.
, “Cost-Effectiveness of Orthogeriatric and Fracture Liaison Service Models of Care for Hip Fracture Patients: A Population-Based Study”, J Bone Miner Res, vol. 32, pp. 203-211, 2017.
, “Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on "real-world" data: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database”, Clin Epidemiol, vol. 10, pp. 1417-1431, 2018.
, “Changes in hip fracture rate before and after total knee replacement due to osteoarthritis: a population-based cohort study”, Ann Rheum Dis, vol. 70, pp. 134-8, 2011.
, “Can the publication of guidelines change the management of early rheumatoid arthritis? An interrupted time series analysis from the United Kingdom”, Rheumatology (Oxford), vol. 54, pp. 2244-8, 2015.
, “Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis”, Calcif Tissue Int, vol. 97, pp. 104-12, 2015.
, “Atopic eczema and fracture risk in adults: A population-based cohort study”, J Allergy Clin Immunol, 2019.
, “Association between NICE guidance on biologic therapies with rates of hip and knee replacement among rheumatoid arthritis patients in England and Wales: An interrupted time-series analysis”, Semin Arthritis Rheum, vol. 47, pp. 605-610, 2018.
, “Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study”, Bmj, vol. 343, p. d7222, 2011.
, “Anti-Osteoporosis Medication Prescriptions and Incidence of Subsequent Fracture Among Primary Hip Fracture Patients in England and Wales: An Interrupted Time-Series Analysis”, J Bone Miner Res, vol. 31, pp. 2008-2015, 2016.
, “Antibiotic treatment and flares of rheumatoid arthritis: a self-controlled case series study analysis using CPRD GOLD”, Sci Rep, vol. 9, p. 8941, 2019.
, ,